Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis

Abstract

Several studies have reported a positive correlation between levels of soluble adhesion molecules in serum or cerebrospinal fluid and cranial MRI activity. We performed a cross-sectional study in 46 patients with newly diagnosed MS and determined levels of soluble intercellular adhesion molecule-1 (sICAM-1) as well as vascular cell adhesion molecule-1 (sVCAM-1) in correlation to the number and area of gadolinium enhancing lesions on cranial magnetic resonance images (MRI). The data revealed a significant positive correlation between sVCAM-1 serum levels and gadolinium enhancing lesions. In addition, CSF to serum ratios for sICAM-1 and sVCAM-1 correlated to MRI activity. In patients with a single enhancing lesion (SEL) there was a negative correlation between the QsCAM and the distance of the SEL to the ventricles. As these adhesion molecules are stable and markers of disease activity in MS, we further investigated sVCAM-1 serum levels during treatment with interferon beta-1b (Betaferon®). Significant increases in serum levels for sVCAM-1 in patients receiving Betaferon were associated with a favourable treatment response after 1 year in 17 out of 19 patients and correlated to decreased MRI activity, whereas stable or reduced sVCAM-1 levels occured more often in non-responders (five out of six patients). Therefore it can be hypothezised that soluble adhesion molecules are released from cerebral endothelial cells as an early immunoregulatory activity of the immune system to reduce cellular traffic across the blood brain barrier and this is further enhanced by IFN-beta treatment.

Keywords

adhesion molecules MRI multiple sclerosis Interferon-beta cerebrospinal fluid cytokines

Get full access to this article

View all access options for this article.

References

Hohlfeld R. (1997) Biotechnological agents for the immunotherapy of multiple sclerosis . Brain 120: 865-916 .

Cross H. (1992) Immune cell traffic control and the central nervous system . Semin Neurosci 4: 213-219 .

Raine C. (1994) Multiple sclerosis: immune system molecule expression in the central nervous system . J Neuropathol Exp Neurol 53: 328-337 .

Hawkins CP et al. (1990) Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers . Brain 113: 365-378 .

Newcombe J et al. (1991) Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue . Brain 114: 1013-1023 .

Katz D et al. (1993) Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis . Ann Neurol 34: 661-669 .

Katz J et al. (1990) Gadolinium enhancing lesions on magnetic resonance imaging: neuropathological findings . Ann Neurol 28: 243-248 .

Giovannoni G et al. (1997) Longitudinal study of soluble adhesion molecules in multiple sclerosis . Neurology 48: 1557-1565 .

Hartung HP et al. (1995) Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: Correlation with magnetic resonance imaging . Ann Neurol 38: 186-193 .

10.

Mossner R et al. (1996) Vascular cell adhesion molecule: a new approach to detect endothelial cell activation in MS and encephalitis in vivo . Acta Neurol Scand 93: 118-122 .

11.

Trojano M et al. (1996) Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings . Neurology 47: 1535-1541 .

12.

Calabresi PA et al. (1997) Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b . Ann Neurol 41: 669-674 .

13.

Kylync M , Karabudak R , Saatci I. (1997) Serial analysis of soluble adhesion molecules and tumor necrosis factor in patients with multiple sclerosis during the treatment with interferon-beta . JNeurol 244 (Suppl. 3): S131-S131 .

14.

Rieckmann P et al. (1997) Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis . Ann Neurol 41: 326-333 .

15.

Stone LA et al. (1995) The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsingremitting multiple sclerosis . Ann Neurol 37: 611-619 .

16.

Rieckmann P et al. (1994) Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse . Neurology 44: 2367-2372 .

17.

Dhib-Jalbut S , Jiang H , Williams GJ. (1996) The effects of interferon beta-1b on lymphocyte-endothelial cell adhesion . J Neuroimmunol 71: 215-222 .

18.

Beck J et al. (1988) Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Acta Neurol Scand 78: 318-323 .

19.

Chofflon M et al. (1992) Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple sclerosis . Eur Cytokine Netw 3: 523-531 .

20.

Rieckmann P et al. (1995) Tumor necrosis factor-a messenger RNA expression in patients with relapsingremitting multiple sclerosis is asociated with disease activity . Ann Neurol 37: 82-88 .

21.

Washington R et al. (1994) Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis . Neurology 35: 89-97 .

22.

Gearing AJH , Newman W. (1993) Circulating adhesion molecules in disease . Immunol Tod 14: 506-512 .

23.

Rieckmann P et al. (1995) Cerebral endothelial cells are a major source for soluble intercellular adhesion molecule- 1 in the human central nervous system . Neuroscience Lett 186: 61-64 .

24.

Rieckmann P et al. (1995) Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells . J Neuroimmunol 60: 9-15 .